Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Lenalidomide: should maintenance therapy after autograft be limited?

Sergio Giralt • 26 Oct 2019
COSTEM 2019
Multiple Myeloma Lenalidomide

Sergio Giralt, MD, Memorial Sloan Kettering Cancer Center, New York, NY, debates the utility, efficacy and limitation of maintenance therapy after autograft in multiple myeloma. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Sergio Giralt

1:12
An update in cellular therapies: gene editing for SCD and immunotherapies for MM
Sergio Giralt • 8 Dec 2023
0:59
The role of radioimmunoconjugates in AML treatment: insights from the SIERRA trial
Sergio Giralt • 8 Dec 2023
2:03
The evolving role of transplantation in multiple myeloma in the age of novel immunotherapeutics
Sergio Giralt • 8 Dec 2023
1:29
Final results of KarMMa-3: ide-cel in R/R MM
Sergio Giralt • 8 Dec 2023

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals